Pierre Poilievre Retains Conservative Leadership After Election Defeat in Canada 
Medvedev Warns World Is Growing More Dangerous but Says Russia Seeks to Avoid Global Conflict 
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
U.S. Approves Over $6.5 Billion in Military Sales to Israel Across Three Defense Contracts 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Trump Orders DHS to Avoid Protests in Democratic Cities Unless Federal Assets Are Threatened 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Venezuela Proposes Amnesty Law and Plans to Transform Helicoide Prison 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
A panel of independent U.S. vaccine experts has announced plans to review the long-standing recommendation for administering the hepatitis B vaccine at birth. The Vaccine Integrity Project, an organization focused on ensuring vaccine safety and efficacy, said it expects to complete its review by early December. The move follows a decision by a federal advisory committee under the Centers for Disease Control and Prevention (CDC) to delay a vote on whether to postpone the first hepatitis B dose for newborns of mothers who test negative for the virus.
The review will analyze decades of scientific research on the safety, effectiveness, and public health outcomes of administering the hepatitis B vaccine within the first 24 hours of life. It will also evaluate the potential risks of delaying the vaccine, including missed opportunities for immunization due to incomplete maternal screening or lack of follow-up.
Currently, the CDC and World Health Organization recommend that all newborns receive the hepatitis B vaccine shortly after birth to prevent mother-to-child transmission. Data show that infants infected at birth or within their first year face up to a 90% chance of developing chronic hepatitis B, which can lead to cirrhosis or liver cancer later in life.
The discussion has gained political attention after President Donald Trump questioned the necessity of giving the vaccine at birth, suggesting instead that it could be delayed until age 12, citing its transmission through sexual contact. However, health experts emphasize that perinatal infection remains a significant transmission route.
Since the introduction of widespread vaccination, hepatitis B infection rates in the United States have dropped by nearly 90%, from about 9.6 per 100,000 people before the vaccine program began to around one per 100,000 in 2018. Currently, six hepatitis vaccines are approved for use in the U.S., continuing to play a vital role in reducing the disease’s prevalence and protecting future generations.
